ABSTRACT
Objetivo: Determinar la respuesta al tratamiento de primera linea, describir las características clínico-patológicas, estimar la sobrevida fibre de progresión (SLP), sobrevida global (SG) según protocolo y según intención de tratamiento de los pacientes con Mieloma Multiple (MM). Materiales y Métodos: Estudio observacional, retrospectivo, tipo serie de casos, descriptivo realizado en el Instituto Nacional de Enfermedades Neoplasicas. Se incluyeron los pacientes diagnosticados de MM con tratamiento de primera linea del 2002 al 2006. Se revisaron 253 historias cllnicas, /35 cumplieron criterios de selección. La estimación de las curvas de sobrevida se realizó por el metodo de Kaplan-Meier. Resultados: La mediana de edad file 59,2 años. Hubo 67 hombres (65,7%). La inmunoglobulina G file mas frecuente (4/,2%). El tratamiento más frecuente fue VAD (62,7%). 18 pacientes (17,6%) tuvieron respuesta completa (RC) y 30 (29,4%) respuesta parcial (RP). Hubo RC en 20,3% y RP en 25% de casos que recibieron VAD. La mediana de SLP fue 12 meses con sobrevida a los 5 aiios de 11,5%. La mediana de SG fue 33 meses con sobrevida a 5 ahos de 31,5%. fJ2mg (>5,5), deterioro renal, número de cursos de VAD y porcentaje de células plasmaticas mostraron menor SG. La mediana de SG por intención de tratar para VAD fue 30 meses con sobrevida a 5 años de 30,3%. Conclusiones: El tratamiento más utilizado file VAD, con respuesta global de 45%. La SLP fue 12 meses, la SG file 33 meses. Se observe menor sobrevida global con fJ2mg (>5,5), deterioro renal, porcentaje de celulas plasmáticas y número de cursos de VAD.
Objective: To determine the response to first-line treatment, describe the clinical and pathological features, estimate the progression-free survival (PFS), overall survival (OS) according to protocol and intention-to-treat patients with multiple myeloma (MM). . Materials and Methods: An observational, retrospective, case series, descriptive study conducted at the Instituto Nacional de Enfermedades Neoplasicas in Lima. We included patients diagnosed of MM with first-line treatment from 2002 to 2006. 253 medical records were reviewed, 135 met the selection criteria. The estimate of the survival curves was performed by the Kaplan-Meier method. Results: The median age was 59.2 years. There were 67 men (65.7%). immunoglobulin G was morefrequent (41.2%). The most frequent treatment was VAD (62.7%). 18 patients (176%) had a complete response (CR) and 30 (29.4%) partial response. There was CR in 20.3% of patients who received VAD. The median PFS was 12 months with 5-year survival of 11.5%. The median OS was 33 months with 5-year survival of 31.5%. The fJ2mg (> 5.5), renal impairment, the number of courses of VAD and the percentage of plasma cells were significantly showed lower Os. The median OS by intention to treat (1TT) VAD was 30 months with 5-year survival of 30.3%. Conclusions: The most common treatment was VAD, with overall response of 45%. PFS was 12 months, OS was 33 months. Lower overall survival was observed with fJ2mg (> 5.5), renal impairment, plasma cell percentage and number of courses of VAD.
Subject(s)
Humans , Male , Adolescent , Adult , Female , Young Adult , Middle Aged , Aged, 80 and over , Multiple Myeloma/drug therapy , Multiple Myeloma/therapy , Survival , Epidemiology, Descriptive , Observational Studies as Topic , Retrospective Studies , Case ReportsABSTRACT
to assess survival rate of mice subjected to cecal ligation and puncture (CLP) treated with copaiba oil subcutaneous injection. Methods: twenty-one BALB/c male mice were randomly distributed into three following groups: Sham (subjected to all surgical procedures except for the CLP procedures); Control (subjected to CLP procedures with no treatment); and Experimental (subjected to CLP procedures treated with copaiba oil, 0.63 ml per kg, injected once a day subcutaneously for five days). Sepsis was induced by CLP procedure and after that, mice were monitored every 6 h till 120 h completed. Survival rate was assessed by the Kaplan-Meier curve and the long-rank test. Results: there was a significant difference on survival of mice subjected to copaiba oil injection (p < 0.0001), survival rate in Control was 0% after 72 h, as expected, but Experimental survival rate was 71.43% till the last observation time (120 h). Conclusion: copaiba oil treatment improved survival in mice subjected to CLP.
analisar a sobrevida de camundongos submetidos à ligadura e perfuração cecal (LPC) tratados com injeção subcutânea de óleo de copaiba. Método: pesquisa experimental com vinte e um camundongos machos BALB/c foram distribuídos randomicamente nos três seguintes grupos: Padrão (submetidos à todos os procedimentos cirúrgicos exceto pelos procedimentos de LPC); Controle (submetidos ao procedimento de LPC e sem tratamento); e Experimental (submetidos ao procedimento de LPC e tratados com óleo de copaiba, 0.63 ml por kg, injetado no subcutâneo uma vez ao dia por cinco dias). Sepse foi induzida por LPC e posteriormente os camundongos foram monitorados a cada 6 h até completar 120 h. A sobrevida foi avaliada pela curva de Kaplan-Meier e pelo teste long-rank. Resultados: houve diferença significante na sobrevida dos animais que receberam injeção de óleo de copaíba, a taxa de sobrevida dos animais do Controle foi de 0% após 72 h, como esperado, porém a taxa de sobrevida dos animais do Experimental foi de 71.43% até o último período de observação (120h). Conclusão: o tratamento com óleo de copaiba aumentou a sobrevida de camundongos submetidos à LPC.